106 research outputs found

    Engineered hydrogels as functional components in controllable neuromodulation for translational therapeutics

    No full text
    Controllable neuromodulation leveraging multimodal triggers synergized with hydrogels represents a transformative therapeutic strategy for pro-regenerative neural repair. Strategic incorporation of programmable neuromodulatory interventions and engineered hydrogels within localized neural niches is critical for clinical translation, characterized by lower invasiveness and greater therapeutic efficacy. This review elucidates the physiochemical features of hydrogels, systematically classifying hydrogel-based neuromodulation into five distinct modes (electrical, ionic, biomechanical, optical, and biochemical) and highlighting the intrinsic multidimensional structural and chemical engineering employed to enhance neuromodulatory performance. Key principles of hydrogel design and fabrication are provided from the perspective of tissue–implant interactions, such as mechanical compatibility, electrointegration, adhesion, and wireless activation. Hydrogels embedded with low-impedance organic and inorganic components, such as conductive polymers and noble metals, are investigated to provide high-level evidence to enable precise cellular stimulation for intrinsic nerve repair, neural prosthesis, and brain–machine interface. Crucially, this review highlights the synergistic integration of these principles into multimodal, closed-loop systems, which combine functions like electrophysiological sensing with on-demand biochemical release for intelligent, autonomous therapies. Finally, this review confronts the critical challenges for clinical translation and discusses future directions, including the potential of artificial intelligence-driven materials design to accelerate the development of next-generation neural interfaces

    Compare of Energy Efficiency of Windows in Aalborg and Chongqing:<strong/>

    No full text
    Focus on window's energy efficiency, this paper compared the difference of windows in Aalborg and Chongqing. The author analysed the designing process, the thermal insulation performances, the sun shading devices and the ventilation of windows in Aalborg and Chongqing respectively. Furthermore, the author explored the reasons for window problems in Chongqing, found out the main barriers to overcome and measures to take for solving the problem. Deeper analysis should be made before the energy efficient windows of Aalborg used in Chongqing.Focus on window's energy efficiency, this paper compared the difference of windows in Aalborg and Chongqing. The author analysed the designing process, the thermal insulation performances, the sun shading devices and the ventilation of windows in Aalborg and Chongqing respectively. Furthermore, the author explored the reasons for window problems in Chongqing, found out the main barriers to overcome and measures to take for solving the problem. Deeper analysis should be made before the energy efficient windows of Aalborg used in Chongqing

    Navigation into novel medical use of bismuth based agents as breakers of antibiotic resistance and antagonist against chemotherapy side effects

    No full text
    Bismuth-based agents have been applied in the treatment of diverse diseases for over two-hundred years owing to their economic, non-toxic, stable and easy-to-use characteristics. Nowadays, the most clinically relevant bismuth medicines such as bismuth subsalicylate, colloidal bismuth subcitrate (CBS), ranitidine bismuth citrate find their main medical use in the treatment of Helicobacter pylori (H. pylori)-associated gastrointestinal diseases. But the rich biological chemistry of bismuth endows it with more potentials in medication other than eradication of H.pylori. In this thesis, the roles of bismuth-based agents in the combat with antibiotic resistance and chemotherapeutic drug induced side effects are explored. A battery of bismuth complexes with bismuth coordinating to nitrogen, oxygen and/or sulfur containing ligands are prepared to establish a compound bank in search of the drug candidates with desired properties. A primary screening gives thirteen bismuth compounds that exhibited antibacterial activity against three Burkholderia cepacia complex (BCC) with MIC ranging from 0.5 to 128 µg mL-1. CBS is found to significantly resensitize BCC to antibiotics, lower the mutation prevention concentration by 2~32-fold and slow down resistance development by 4 folds when it is used together with tetracycline. Either physical mixing or complexation of bismuth with a small molecule Hinokitiol dramatically enhanced the antimicrobial activity of bismuth compounds against both planktonic and biofilm Pseudomonas aeruginosa, which shed light on a novel strategy to tune the antimicrobial activity of Bi(III) compounds. Metallo-β-lactamase (MBL) such as NDM-1 is a zinc enzyme that empowers bacteria with resistance to almost all β-lactam antibiotics. Bismuth compounds are found to be a novel class of MBL inhibitor. Through metal displacement mechanism, bismuth compounds resensitize a panel of MBL positive bacteria to meropenem with its MIC dropped by 8~32 folds. The bioactivity of compounds was found to correlate with the ligand type and coordination environment of Bi(III) ions. CBS suppresses the resistance development of NDM-1 positive E. coli. Animal study shows that the combination therapy of CBS and meropenem greatly raises the survival rate of infected mice in systemic infection model and reduce significantly bacterial loads in mouse bladder in urinary tract infection model. Several bismuth drugs such as BSS and CBS are reported to antagonize cisplatin-induced nephrotoxicity via the induction of metallothionein. Through cell-based screening, two types of bismuth compounds, bismuth tetraphenylporphyrinate (Bi(TPP)) and bismuth thiolates are identified to have higher cytoprotective activity than either CBS or BSS. Animal studies reveal that pretreatment of Bi(TPP) significantly protect the renal function and raise the survival rate of mice receiving cisplatin administration while showing no compromisation on the antineoplastic action of CDDP. Protective mode of action of Bi(TPP) was unveiled via transcriptomic analysis. Bi(TPP) was found to upregulate some key survival factors i.e., Pik3cd, Egf, Igf2 and downregulate some key death factors i.e., Fas, Tnf, Casp8 in signaling pathway related to apotosis and inflammation. Bioinformatics study further indicates that, beyond MT induction, protection offered by Bi(TPP) tightly correlates with protein binding, ion binding, catalytic activity, apoptotic signaling.published_or_final_versionChemistryDoctoralDoctor of Philosoph

    Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia

    No full text
    Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encapsulated into polyethylene glycol modified poly (lactic-co-glycolic acid) nanoparticles (IRAK/ABT-NP) to enhance synergistic therapy of T-ALL. The formulation was optimized to achieve high drug loading using Box-Behnken design and response surface methodology. The optimal parameter comprised 2.98% polymer in acetonitrile, a ratio of oil phase to water phase of 1:8.33, and 2.12% emulsifier concentration. High drug loading and uniform spherical shape was achieved. In vitro release study showed sustained release of IRAK1/4 inhibitor for 72 hours as well as sustained release of ABT-737 for more than 120 hours. Uptake efficiency of IRAK/ABT-NP and induced apoptotic T-ALL fraction by IRAK/ABT-NP were much higher than the IRAK1/4 and ABT-737 combined solution. IC50 of IRAK/ABT-NP was two-fold lower than free drug combination in Jurkat cells. Additionally, we conducted in&nbsp;vivo experiments in which IRAK/ABT-NP exhibited greater cytotoxicity toward T-ALL cells, the capacity to significantly restore white blood cell number in peripheral blood, and improved survival time of T-ALL mouse model compared to the IRAK1/4 and ABT-737 combined solution. Keywords: T cell acute lymphoblastic leukemia, IRAK1/4 inhibitor, ABT-737, Box-Behnken design and response surface methodology, PEG-PLG

    )

    No full text
    corecore